Doctors warn that Bulgaria’s healthcare system still lacks a sustainable framework for genomic diagnostics, patients are ...
Eli Lilly advances CRISPR collaboration with Scribe Therapeutics for neurological and neuromuscular disorders; European ...
Natus Medical Incorporated has announced the global launch of the autoSCORE™ analysis tool, spreading the availability of the ...
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b ...
Whether you’re managing a lethal-force encounter, running a stage in competition or working a timed drill from concealment, ...
Building on the recent U.S. FDA Fast Track Designation for AJ201 (Rosolutamide) and encouraging Phase 2 clinical results, AnnJi presented two scientific abstracts spanning translational transcriptomic ...
Research and development (R&D) expenses: R&D expenses were $95.4 million and $81.8 million for the quarters ended December 31, 2025 and 2024, respectively. R&D expenses were $398.3 million and $281.4 ...
PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, today announced regulatory ...
Japan Rare Disease Patient Identification Services Market Growth Projections US$110.92Mn By 2033, Growth In Genomics. EINPresswire/ -- Market Size and Growth (2026) The Japan Rare Disease Patient ...
Tapering, which is a form of planned reduction in training volume before a major event, thrives because it solves snags previously created — having accumulated more training load than one could ...
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease.
Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results